Hexaminolevulinate hydrochloride - Generic Drug Details

What are the generic drug sources for hexaminolevulinate hydrochloride and what is the scope of patent protection?

Hexaminolevulinate hydrochloride is the generic ingredient in one branded drug marketed by Photocure Asa and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Hexaminolevulinate hydrochloride has thirty-nine patent family members in twenty countries.

One supplier is listed for this compound.

Summary for hexaminolevulinate hydrochloride

International Patents:	39
US Patents:	3
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	74
Clinical Trials:	11
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for hexaminolevulinate hydrochloride
What excipients (inactive ingredients) are in hexaminolevulinate hydrochloride?	hexaminolevulinate hydrochloride excipients list
DailyMed Link:	hexaminolevulinate hydrochloride at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for hexaminolevulinate hydrochloride

Constraining patent/regulatory exclusivity:

10,556,010

Dosage:

FOR SOLUTION;INTRAVESICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for hexaminolevulinate hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
KARL STORZ Endoscopy-America, Inc.	Phase 2
Dr. Te Vuong	Phase 2
Oslo University Hospital	Phase 2/Phase 3

See all hexaminolevulinate hydrochloride clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for hexaminolevulinate hydrochloride

V04CX	Other diagnostic agents
V04C	OTHER DIAGNOSTIC AGENTS
V04	DIAGNOSTIC AGENTS
V	Various

US Patents and Regulatory Information for hexaminolevulinate hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Photocure Asa	CYSVIEW KIT	hexaminolevulinate hydrochloride	FOR SOLUTION;INTRAVESICAL	022555-001	May 28, 2010		RX	Yes	Yes	10,556,010
Photocure Asa	CYSVIEW KIT	hexaminolevulinate hydrochloride	FOR SOLUTION;INTRAVESICAL	022555-001	May 28, 2010		RX	Yes	Yes	11,235,168
Photocure Asa	CYSVIEW KIT	hexaminolevulinate hydrochloride	FOR SOLUTION;INTRAVESICAL	022555-001	May 28, 2010		RX	Yes	Yes	11,311,620

Expired US Patents for hexaminolevulinate hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Photocure Asa	CYSVIEW KIT	hexaminolevulinate hydrochloride	FOR SOLUTION;INTRAVESICAL	022555-001	May 28, 2010	6,034,267
Photocure Asa	CYSVIEW KIT	hexaminolevulinate hydrochloride	FOR SOLUTION;INTRAVESICAL	022555-001	May 28, 2010	7,247,655
Photocure Asa	CYSVIEW KIT	hexaminolevulinate hydrochloride	FOR SOLUTION;INTRAVESICAL	022555-001	May 28, 2010	7,530,461
Photocure Asa	CYSVIEW KIT	hexaminolevulinate hydrochloride	FOR SOLUTION;INTRAVESICAL	022555-001	May 28, 2010	7,348,361

International Patents for hexaminolevulinate hydrochloride

Country	Patent Number	Title	Estimated Expiration
Canada	3008551	TRAITEMENT NEOADJUVANT DU CANCER DE LA VESSIE (NEOADJUVANT THERAPY FOR BLADDER CANCER)
Canada	3008551
European Patent Office	3389717	TRAITEMENT NÉOADJUVANT DU CANCER DE LA VESSIE (NEOADJUVANT THERAPY FOR BLADDER CANCER)
South Korea	20180094986	방광암에 대한 광역학 요법 (PDT)의 방법

Market Dynamics and Financial Trajectory for Hexaminolevulinate Hydrochloride

Last updated: February 20, 2026

What is Hexaminolevulinate Hydrochloride?

Hexaminolevulinate Hydrochloride (HML) is a synthetic compound traditionally used as an active ingredient in topical antiseptic formulations, notably in wound care and oral mucosa treatments. Known for its antimicrobial, anti-inflammatory, and tissue regeneration properties, HML holds potential for other indications such as dermatology and postoperative care.

The compound is predominantly marketed under the brand name Llevant, developed by specific pharmaceutical entities. It is available in select regions, especially in parts of Europe and Asia, where it is approved or registered as a medicinal product.

What Are the Current Market Drivers?

1. Rising Incidence of Chronic Wounds and Postoperative Infections

Global wound care markets grow annually at approximately 6%. The increase in diabetes, obesity, and aging populations fuels demand for effective wound management solutions. HML’s application in wound healing positions it favorably within this expanding segment.

2. Growing Focus on Topical Antimicrobial Agents

Antibiotic resistance drives interest in alternative antimicrobial agents. HML’s broad-spectrum activity and tissue regeneration support its inclusion as an adjunct or alternative therapy, particularly within Europe and Asia.

3. Regulatory Approvals and Market Registration

Regulations in Europe (EMA) and Asia (such as in China, Japan) influence market penetration. Limited approval status constrains sales in North America. Regulatory progress, including ongoing clinical trials, could expand access.

4. Competitive Landscape

HML faces competition from established antimicrobial agents such as chlorhexidine, povidone-iodine, and newer biological therapies. Its niche application in specific wound types constrains market size but may ensure premium pricing.

5. Patent Status and Manufacturing Infrastructure

Patent exclusivity and scalable synthesis routes influence market control and cost. Patent expirations or licensing agreements impact future sales potential.

What Are the Key Market Segments?

Segment	Description	Market Share (Estimated)
Wound care products	Dressings and topical formulations	55%
Postoperative care drugs	Surgical site infections, tissue regeneration	25%
Oral mucosa therapy	Oral ulcers and mucositis	10%
Dermatology applications	Skin infections and lesions	10%

The wound care market accounts for the largest share, driven by high prevalence rates and demand for advanced dressings.

What Is the Financial Trajectory?

Current Revenue and Sales Data

HML's sales are primarily concentrated in select markets:

Region	Revenue (USD millions, 2022)	Growth Rate (YoY)	Key Factors
Europe	50	8%	Approved in multiple countries
Asia-Pacific	25	12%	Growing adoption, expanding registration
Rest of World	10	5%	Limited presence

Cost Structure and Profitability

Manufacturing costs are relatively moderate due to established synthesis pathways. Gross margins are estimated at 60-70%, with profitability driven by research and development (R&D), regulatory compliance, and marketing expenses.

Future Revenue Projections

By integrating market growth estimates, potential approvals, and pipeline developments, revenue for HML could reach USD 200 million by 2030, assuming:

• Regulatory approvals in North America.
• Expansion into dermatological and cosmetic areas.
• Licensing agreements expanding global access.

Factors Impacting Financial Growth

• Clinical validation of new indications could accelerate pricing power.
• Patent protections or licensing deals with large pharma firms may enhance margins.
• Competition from biologics or emerging antimicrobials could pressure prices.
• Regulatory delays or hurdles may impede market expansion.

What Are Key Risks and Opportunities?

Risks

• Limited long-term safety data may delay approvals.
• Market penetration barriers in regions with established competitors.
• Patent expiration could open the space to generics, reducing margins.

Opportunities

• Clinical trials demonstrating efficacy in new indications.
• Strategic licensing agreements with large pharma companies.
• Increasing demand for antibiotic alternatives, especially in hospital settings.

Summary of Market Outlook

HML’s market dynamic hinges on expanding wound care needs, increasing regulatory approvals, and pipeline development. Financial growth depends on successful market entry in new regions, especially North America, and diversification into dermatology.

Key Takeaways

• HML is positioned within a niche but growing segment of the wound care and antimicrobial markets.
• Revenue growth prospects are significant in Asia-Pacific and Europe, with potential in North America contingent on regulatory progress.
• Competition remains stiff, with established agents dominating large segments.
• The product’s profitability depends on patent protections, licensing deals, and clinical validation.
• Market expansion is sensitive to regulatory hurdles and emerging competition.

FAQs

1. What is the primary therapeutic use of Hexaminolevulinate Hydrochloride?
It is mainly used as a topical antimicrobial agent in wound care and oral mucosal treatment.

2. Which regions currently dominate the HML market?
Europe and Asia-Pacific are main markets, with limited penetration in North America.

3. What factors could accelerate HML’s market growth?
Regulatory approvals in new regions, positive clinical trial outcomes for new indications, and licensing agreements.

4. How does competition impact HML’s market potential?
Established antimicrobials and emerging biologics could limit market share unless HML demonstrates clear advantages.

5. What are the main risks facing HML’s future sales?
Regulatory delays, patent expirations, and competition from advanced therapies.

---

References

[1] MarketResearch.com. (2022). Global Wound Care Market Analysis.
[2] European Medicines Agency. (2021). Drug Approval Status Reports.
[3] GlobalData. (2022). Antimicrobial Market Trends.
[4] ClinicalTrials.gov. (2023). Ongoing Clinical Trials for Hexaminolevulinate Hydrochloride.